Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease

Infliximab Reduces the Frequency of Interleukin 17-Producing Cells and the Amounts of Interleukin 17 in Patients With Rheumatoid Arthritis

(2016) Hui Shen et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Th17 Cells

(2012) Mohan S. Maddur et al.   AMERICAN JOURNAL OF PATHOLOGY

Whatʼs the next best cytokine target in IBD?

(2012) Thomas T. MacDonald et al.   INFLAMMATORY BOWEL DISEASES

IL-17/IFN-γ Interactions Regulate Intestinal Inflammation in TNBS-Induced Acute Colitis

(2012) Yu Jin et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Review article: infliximab for Crohn’s disease treatment - shifting therapeutic strategies after 10 years of clinical experience

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Chemokine CXCL11 links microbial stimuli to intestinal inflammation

(2011) Z. Liu et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Th1 Responses Are More Susceptible to Infliximab-Mediated Immunosuppression Than Th17 Responses

(2011) Kenji Kanayama et al.   DIGESTIVE DISEASES AND SCIENCES

New Pathogenic Paradigms in Inflammatory Bowel Disease

(2011) Antonio Di Sabatino et al.   INFLAMMATORY BOWEL DISEASES

Interleukin (IL)-23 Suppresses IL-10 in Inflammatory Bowel Disease

(2011) Zhanju Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Th17 Cells Induce Colitis and Promote Th1 Cell Responses through IL-17 Induction of Innate IL-12 and IL-23 Production

(2011) T. Feng et al.   JOURNAL OF IMMUNOLOGY

The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity

(2011) Z. Liu et al.   JOURNAL OF LEUKOCYTE BIOLOGY

T helper 17 cell heterogeneity and pathogenicity in autoimmune disease

(2011) Kamran Ghoreschi et al.   TRENDS IN IMMUNOLOGY

Role of IL-21 in inflammatory bowel disease

(2010) Francesco Pallone et al.   Expert Review of Clinical Immunology

The Genetics of Crohn's Disease

(2009) Johan Van Limbergen et al.   Annual Review of Genomics and Human Genetics

Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease

(2009) Giovanni Monteleone et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease

(2009) Zhanju Liu et al.   INFLAMMATORY BOWEL DISEASES

Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis

(2009) Yasunori Kageyama et al.   Modern Rheumatology

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potential role of Th17 cells in the pathogenesis ofinflammatory bowel disease

(2009) Zhan-Ju Liu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Regulation of Gut Inflammation and Th17 Cell Response by Interleukin-21

(2008) Daniele Fina et al.   GASTROENTEROLOGY

Interleukin 21: a cytokine/cytokine receptor system that has come of age

(2008) Warren J. Leonard et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses

(2008) Giovanni Monteleone et al.   TRENDS IN IMMUNOLOGY

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

(2007) Rosanne Spolski et al.   Annual Review of Immunology